- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Infusions of dalbavancin.
Acute bacterial Gram +ve skin and skin structure infections
1.5g dalbavancin administered as one infusion, or as 1g dalbavancin followed one week later by 500mg dalbavancin.
Patients with Renal Impairment
Creatinine clearance less than 30ml/minute and haemodialysis not regular (less than 3 times a week)
1g dalbavancin administered as one infusion, or as 750mg dalbavancin followed one week later by 375mg dalbavancin.
For intravenous infusion over 30 minutes. Reconstitute and dilute before use.
Children under 18 years
Precautions and Warnings
Moderate hepatic impairment
Renal impairment - creatinine clearance below 30 ml/minute
Reduce dose in patients with creatinine clearance below 30ml/min
Advise ability to drive/operate machinery may be affected by side effects
Consult national/regional policy on the use of anti-infectives
Use additional systemic antibiotic if anaerobic/resistant bacteria present
Dilute and use as an infusion
Suspend treatment or reduce rate until infusion reactions resolve
Consider pseudomembranous colitis if patient presents with diarrhoea
Superinfection may occur during therapy
Discontinue at once if pseudomembranous colitis occurs
Discontinue if allergic reaction occurs
Pregnancy and Lactation
Use dalbavancin with caution during pregnancy.
The manufacturer does not recommend using dalbavancin during pregnancy. Animal studies have shown teratogenic effects. Human data is limited and as such a potential risk cannot be ruled out.
Use dalbavancin with caution during breastfeeding.
The manufacturer advises that the patient either discontinues dalbavancin or discontinues breastfeeding. Animal data reports significant levels of dalbavancin in the breast milk, however the presence in human breast milk and the effect on exposed infants are unknown. LactMed (2015) suggests that because oral absorption of dalbavancin is poor, an effect on the breastfed infant is unlikely. Monitor the infant for potential effects on the gastrointestinal tract.
"Red man" syndrome (flushing of upper body)
Abnormal liver function tests
Alanine aminotransferase increased
Aspartate aminotransferase increased
Gamma glutamyl transferase (GGT) increased
Increase in alkaline phosphatase
Increase in lactate dehydrogenase
Increase of liver transaminases
Increased platelet count
Increased uric acid level
Increases in hepatic enzymes
Infusion related reaction
Rise in body temperature
Urinary tract infections
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: August 2019
Summary of Product Characteristics: Xydalba 500 mg powder for concentrate for solution for infusion. Correvio UK Ltd. Revised December 2018.
US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
Available at: https://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT
Dalbavancin. Last revised: 07 February 2019
Last accessed: 06 August 2019
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.